Latest From Anesiva Inc.
Wyeth (Pfizer) and Mochida Pharmaceutical have ended a licensing deal for a novel class of pain treatments discovered by the mid-sized Japanese firm.
Acceleron Pharma, a privately held US biopharmaceutical company focused on the discovery, development, manufacture and commercialisation of biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases, has named Melissa Morandi vice-president of quality and Dr Kenneth Attie vice-president of medical research. Ms Morandi joins from Anesiva, where she was vice-president of quality, while Dr Attie was previously vice-president of clinical development and medical affairs at Altus Pharmaceuticals.
Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated.
- Therapeutic Areas
- Neurology, Nervous System
- Corgentech Inc.
- North America
- Parent & Subsidiaries
- Anesiva Inc.
- Senior Management
Michael L Kranda, CEO & Pres.
William Houghton, MD, SVP, CMO
John H Tran, VP, Fin., Chief Accounting Officer
John Donovan, MD, Exec. Dir., Bus. Dev.
- Contact Info
Phone: (650) 624-9600
400 Oyster Point Blvd.
S. San Francisco, CA 94080
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.